OBI Pharma, Inc.

Equities

4174

TW0004174008

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-05-12 EDT			5-day change	1st Jan Change
61.2 ^TWD	-0.81%		-0.49%	-11.82%

05-10	Obi Pharma, Inc. Announces the Termination of License Agreement with Odeon for the Rights of Obi-999 and Obi-833 in China, Hong Kong and Macau	CI
03-26	OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

OBI Pharma, Inc. Announces Resignation of Yun Yen as Chairperson and Director, Effective December 29, 2023

December 20, 2023 at 04:35 am

OBI Pharma, Inc. announced the The Company received the resignation letter of Dr. Yun Yen on December 20, 2023, to resign his position as Chairperson and director of the Company. The effective date is set on December 29, 2023.

Latest news about OBI Pharma, Inc.

Obi Pharma, Inc. Announces the Termination of License Agreement with Odeon for the Rights of Obi-999 and Obi-833 in China, Hong Kong and Macau	05-10	CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
Obi Pharma, Inc. Announces the Termination of Obi-3424-001 Trial While Continuing the Collaboration Of obi-3424 with Partners	03-11	CI
OBI Pharma, Inc. Announces Adagloxad Simolenin (OBI-822) Receives Positive 1st Interim Analysis Recommendation, Recommending the Continues of the Phase III TNBC Trial	01-31	CI
OBI Pharma, Inc. Announces OBI-992 TROP2 ADC Has Been Granted by US FDA to Proceed to Phase I/II Human Clinical Trial	01-03	CI
OBI Pharma, Inc. Announces Resignation of Yun Yen as Chairperson and Director, Effective December 29, 2023	12-20	CI
Obi Pharma, Inc. Files the Application of Phase I/II Human Clinical Trial for OBI-992 TROP2 ADC to US FDA	12-01	CI
OBI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
OBI Pharma, Inc. Announces Head Office Address Change	11-06	CI
OBI Pharma, Inc. Announces Internal Audit Officer Changes	11-06	CI
OBI Pharma, Inc. Announces CFO Changes	11-06	CI
OBI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
OBI Pharma, Inc. Announces Executive Changes	23-08-07	CI
OBI Pharma, Inc. Announces Appointment of Yun Yen as the Chairman	23-06-27	CI
OBI Pharma, Inc. Announces Appointment of Yun Yen as Natural-Person Director	23-06-27	CI
OBI Pharma, Inc. Announces COVID-19 Vaccine, BCVax, Has Been Granted by TFDA to Proceed to Phase I Clinical Trial	23-06-02	CI
OBI Pharma Appoints Heidi Wang as Chief Executive Officer	23-06-02	CI
OBI Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
OBI Pharma, Inc. Files the Application of Phase I Human Clinical Trial for COVID-19 Vaccine, BCVax, to TfDA	23-03-31	CI
OBI Pharma, Inc.(TPEX:4174) dropped from FTSE All-World Index	23-03-20	CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Obi Pharma, Inc. Files Application for Phase II Human Clinical Trial of First-In-Class Novel Prodrug, Obi-3424, to TFDA	23-02-02	CI
OBI Pharma, Inc. Announces Demise of Chairman of the Board, Michael Chang	22-12-29	CI
United States Patent and Trademark Office Grants Patent for OBI-866 Immunogenic/Therapeutic Glycan Compositions and Uses Thereof	22-12-23	CI

Chart OBI Pharma, Inc.

Duration

Period

More charts

Company Profile

OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OBI PHARMA, INC.	-11.82%	436M
MODERNA, INC.	+26.37%	44.96B
IQVIA HOLDINGS INC.	-1.01%	42.65B
LONZA GROUP AG	+46.00%	41.85B
CELLTRION, INC.	-5.31%	29.04B
ICON PUBLIC LIMITED COMPANY	+9.34%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	19.03B
BIO-TECHNE CORPORATION	+6.23%	12.75B
MEDPACE HOLDINGS, INC.	+26.99%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.75B

Other Biotechnology & Medical Research